clinical trial · NCT04586231
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Merck Sharp & Dohme LLC·phase3·active not recruiting·n = 747
Carcinoma, Renal CellBelzutifanLenvatinibCabozantinib
brief summary
This study will compare the efficacy and safety of belzutifan + lenvatinib versus cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy. The primary hypothesis is that belzutifan + lenvatinib is superior to cabozantinib in terms of progression-free survival or overall survival.
started
Feb 25, 2021
primary completion
Feb 2, 2026
completion
Feb 11, 2027
last updated
Nov 6, 2026
official title
An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination With Lenvatinib (MK-7902) vs Cabozantinib for Treatment in Participants With Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol